게인 테라퓨틱스GANX 주가

Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate

Gain Therapeutics’ Parkinson’s candidate GT-02287 showed durable clinical stability and biomarker improvements in extended Phase 1b data.

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph continues, with a difference of 4.8 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150 Most common benefits reported by study participants include meaningful improvements in specific functional areas such as smell and taste, sleep, and balance or gait BETHESDA,

♻️ 재탕[8-K] 중대 사건 — FORM 8-K

3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced

Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.

Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss

Gain Therapeutics, Inc. (NASDAQ:GANX) shares rose 3.

Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 2025

[10-Q] 분기 실적 — 10-Q

[8-K] 중대 사건 — 8-K

3 US Biotechs Developing Parkinson’s Therapies

Global markets may be dealing with inflation, shifting rate expectations, and energy volatility, but companies tackling long-term health challenges like Parkinson’s disease are still pushing ahead.

[DEF 14A] 주주총회 위임장 — DEF 14A